Leerink Partners Initiates Coverage on Retension Pharmaceuticals (NASDAQ:RTSN)

Analysts at Leerink Partners began coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a report released on Tuesday, Zacks reports. The brokerage set a “strong-buy” rating on the stock.

RTSN has been the subject of a number of other reports. Guggenheim started coverage on Retension Pharmaceuticals in a report on Monday. They set a “buy” rating and a $55.00 price objective for the company. Oppenheimer initiated coverage on Retension Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $50.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $52.50.

Retension Pharmaceuticals Trading Down 1.6%

RTSN opened at $11.60 on Tuesday. Retension Pharmaceuticals has a 1 year low of $9.66 and a 1 year high of $18.64.

Insider Buying and Selling at Retension Pharmaceuticals

In other Retension Pharmaceuticals news, CEO Eric Keller purchased 20,800 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the transaction, the chief executive officer directly owned 423,377 shares of the company’s stock, valued at $5,080,524. This represents a 5.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Franklin Berger purchased 10,000 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $120,000.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at approximately $120,000. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.